Abstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
March 31, 2020
Assignee:
MannKind Corporation
Inventors:
Marshall Grant, Paul Menkin, Grayson W. Stowell
Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Type:
Grant
Filed:
January 10, 2018
Date of Patent:
March 17, 2020
Assignee:
Allegro Pharmaceuticals, LLC
Inventors:
Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
Abstract: Template-fixed ?-hairpin peptidomimetics of the general formulae wherein Z is a chain of 11 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.
Type:
Grant
Filed:
September 13, 2018
Date of Patent:
February 18, 2020
Assignees:
POLYPHOR LTD., UNIVERSITAT ZURICH
Inventors:
Steven J. Demarco, Kerstin Moehle, Heiko Henze, Odile Sellier, Francoise Jung, Frank Gombert, Daniel Obrecht, Christian Ludin
Abstract: In various embodiments, the present invention provides a process for separating target proteins from non-target proteins in a sample comprising increasing the concentration of the target proteins and non-target proteins in the sample and subsequently delivering the concentrated sample to a chromatography device. In other embodiments, the invention relates to a process for increasing the capacity of a chromatography device for a target protein by delivering a concentrated sample comprising the target protein to a chromatography device.
Type:
Grant
Filed:
June 11, 2015
Date of Patent:
February 4, 2020
Assignee:
EMD Millipore Corporation
Inventors:
Venkatesh Natarajan, Herbert Lutz, Bala Raghunath
Abstract: To provide a peptide that selectively activates type 2 neuromedin U receptor and is chemically stable under physiological conditions. A peptide represented by Formula (1) described in the specification.
Type:
Grant
Filed:
January 19, 2018
Date of Patent:
February 4, 2020
Assignees:
TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, KYOTO PHARMACEUTICAL UNIVERSITY
Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
February 4, 2020
Assignee:
The George Washington University a Congressionally Chartered Not-for-Profit Corporation
Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
Type:
Grant
Filed:
July 22, 2019
Date of Patent:
December 31, 2019
Assignees:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, OCHSNER CLINIC FOUNDATION, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY
Inventors:
Robert C. Gensure, Joshua Sakon, Osamu Matsushita, Tulasi Ponnapakkam
Abstract: Provided is a composition for preventing, treating or improving hair loss and promoting hair generation and hair growth, comprising a CXCL1 protein as an active ingredient. Further, provided is a composition for preventing, treating or improving hair loss and promoting hair generation and hair growth, comprising a CXCL1 protein and minoxidil as an active ingredient. The CXCL1 protein according to the present disclosure has no side effects at the time of treating hair loss and an excellent hair generation effect even in a short time and thus can be used as pharmaceutical products and usefully used as quasi-drugs, cosmetics and health functional foods.
Abstract: Disclosed are compositions and methods for treatment of atherosclerosis and atherosclerotic plaques. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerosis. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerotic plaques. In particular, compositions comprising a plaque-homing element, a CendR-activating element, and a plaque-inhibiting element are disclosed.
Type:
Grant
Filed:
June 27, 2016
Date of Patent:
December 10, 2019
Assignee:
Sanford Burnham Prebys Medical Discovery Institute
Inventors:
Erkki Ruoslahti, Tambet Teesalu, Lauri Paasonen
Abstract: A polymer compound has a group represented by Formula (1) or Formula (2) in a side chain. (In Formula (1), X1 represents a neutral amino acid residue or an ?-aminoalkanoic acid residue, X2 represents a membrane-permeable peptide residue, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, and a represents a number of from 1 to 50.) (In Formula (2), X4 represents a neutral amino acid residue or an ?-aminoalkanoic acid residue, X5 represents a membrane-permeable peptide residue, X6 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, an acyl group having 1 to 6 carbon atoms, an arylsulfonyl group, or a carboxyl group, and b represents a number of from 1 to 50.).
Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
December 10, 2019
Assignee:
The George Washington University a Congressionally Chartered Not-for-Profit Corporation
Abstract: The present disclosure is directed to co-administration of high dose Vitamin D3, heat shock proteins, glutathione, and kits provided for co-administration of these compositions, for the treatment of patients with chronic inflammation and chronic diseases.
Abstract: Disclosed are isolated cytotoxic peptides having similar sequences as the basic region (BR) of Hexamethylene Bisacetamide Inducible Protein 1 (HEXIM1). Preferred embodiments include QLGKKKHRRRPSKKKRHW (SEQ ID No: 3). QLGRRRHRRRPSRRRRHW (SEQ ID No: 4) and QLGKKILAARPSKKKRHW (SEQ ID No: 5). Also encompassed are isolated nucleic acid molecules encoding for the claimed peptides, vectors comprising the isolated nucleic acids, compositions comprising peptides conjugated to cell-targeting or penetrating peptides or antibodies, nucleic acid molecules or vectors expressing conjugates thereof; methods of treating or preventing diseases or conditions, including cancers and obesity as well as a method of eliminating undifferentiated stem cells.
Type:
Grant
Filed:
March 3, 2016
Date of Patent:
December 10, 2019
Assignee:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Abstract: This invention relates to the in vitro production of cyclic peptides using cyanobacterial enzymes, such as patellamide biosynthesis enzymes. Linear peptide substrates are cyclized using an isolated cyanbacterial macrocyclase, such as PatG from Prochloron spp. Before cyclization, residues in the linear peptide substrates may be heterocyclized using isolated cyanbacterial heterocyclasses, such as PatD or TruD heterocyclase. Methods of the invention may be useful, for example, for the production of cyclic peptidyl molecules, including cyclotides, such as katalas, and cyanobactins, such as patellamides and telomestatins, for example for use in the development of therapeutics.
Type:
Grant
Filed:
August 22, 2017
Date of Patent:
December 3, 2019
Assignee:
Oxford University Innovation Limited
Inventors:
Wael Houssen Ibrahim, Marcel Jaspars, Margaret Smith, James Naismith, Jesko Koehnke, Andrew Bent, Nicholas Westwood
Abstract: Potent modulators of RNA function can be assembled in cellulo by using the cell as a reaction vessel and a disease-causing RNA as a catalyst. When designing small molecule effectors of function, a balance between permeability and potency must be struck. Low molecular weight compounds are more permeable while higher molecular weight compounds are more potent. The advantages of both types of compounds could be synergized if low molecular weight molecules could be transformed into potent, multivalent ligands via a reaction catalyzed by binding to a target in cells expressing a genetic defect. We demonstrate that this approach is indeed viable in cellulo. Small molecule modules with precisely positioned alkyne and azide moieties bind adjacent internal loops in r(CCUG)exp, the causative agent of myotonic dystrophy type 2 (DM2), and are transformed into oligomeric, potent inhibitors of DM2 RNA dysfunction via a 1,3 Huisgen dipolar cycloaddition reaction, a variant of click chemistry.
Abstract: The present invention provides an injectable pharmaceutical composition containing the following components: (a) one or more kinds of peptides selected from a peptide represented by the formula (1): wherein the bond between Cys and Cys is a disulfide bond, Leu-OH shows that the C-terminal of Leu is a free carboxyl group, and other bond is a peptide bond, a peptide consisting of the amino acid sequence shown by Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1) and salts thereof, (b) trehalose or trehalose hydrate, and (c) a pH adjuster.
Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.
Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.
Type:
Grant
Filed:
March 2, 2015
Date of Patent:
October 29, 2019
Assignee:
Saint Regis Mohawk Tribe
Inventors:
James N. Chang, Orest Olejnik, Bruce A. Firestone
Abstract: The present invention provides a synthetic blood vessel and use thereof in drug screening, drug delivery and prognoses of cerebrovascular dysfunction.